| Autor: |
Hiromi Nagata, Hironori Tsujimoto, Yoshihisa Yaguchi, Keita Kouzu, Yujiro Itazaki, Yusuke Ishibashi, Satoshi Tsuchiya, Takao Sugihara, Nozomi Ito, Manabu Harada, Shinsuke Nomura, Yoshitaka Utsumi, Hideyuki Shimazaki, Yoji Kishi, Hideki Ueno |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Surgical Case Reports, Vol 6, Iss 1, Pp 1-6 (2020) |
| Druh dokumentu: |
article |
| ISSN: |
2198-7793 |
| DOI: |
10.1186/s40792-020-0774-7 |
| Popis: |
Abstract Background Trastuzumab (T-mab)-based chemotherapy is a standard regimen for human epithelial growth factor 2 (HER2)-positive gastric cancer. However, some patients have demonstrated a change in HER2 status after T-mab-based treatment of breast cancer. We report a rare case of mixed adenoneuroendocrine carcinoma with loss of HER2 positivity after T-mab-based chemotherapy for HER2-positive gastric cancer. Case presentation A 60-year-old man presented with a mass of the upper abdomen, which was diagnosed as adenocarcinoma with a HER2 score of 3+ by endoscopic biopsy. He received seven cycles of combination chemotherapy with capecitabine, cisplatin, and T-mab. Subsequently, he underwent open total gastrectomy, distal pancreatosplenectomy, and extended left hepatic lobectomy as a conversion surgery. The surgically resected specimen demonstrated both adenocarcinoma and neuroendocrine components; therefore, it was diagnosed as HER2-negative mixed adenoneuroendocrine carcinoma. Although the patient received additional chemotherapy, multiple liver metastases appeared at 3 months postoperatively and he died at 6 months postoperatively because of the rapidly progressing metastatic tumor. Conclusions We encountered a rare case of rapidly progressive mixed adenoneuroendocrine carcinoma that was negative for HER2 expression after T-mab treatment combined with chemotherapy. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Full text from SpringerLink